Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review

References

• NCI. Breast Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute. General Information about Breast Cancer. Available from:https://www.cancer.gov/types/breast/hp/breast-treatment-pdq#section/_1. Accessed 612, 2018.
   Google Scholar
• Caswell-JinJL, PlevritisSK, TianL, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectrum. 2018;2(4):pky062. doi:10.1093/jncics/pky06230627694
   PubMed Web of Science ®Google Scholar
• WeissA, Chavez-MacGregorM, LichtensztajnDY, et al. Validation study of the american joint committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol. 2018;4(2):203–209. doi:10.1001/jamaoncol.2017.429829222540
   PubMed Web of Science ®Google Scholar
• DawoodS, BroglioK, EnsorJ, HortobagyiGN, GiordanoSH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21(11):2169–2174. doi:10.1093/annonc/mdq22020427349
   PubMed Web of Science ®Google Scholar
• BalduzziS, MantarroS, GuarneriV, et al.Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014;(6):CD006242. doi:10.1002/14651858.CD006242.pub224919460
   PubMed Web of Science ®Google Scholar
• GiulianoM, SchettiniF, RognoniC, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369. doi:10.1016/S1470-2045(19)30420-631494037
   PubMed Web of Science ®Google Scholar
• PerouCM, SorlieT, EisenMB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/3502109310963602
   PubMed Web of Science ®Google Scholar
• PratA, PerouCM. Deconstructing the molecular portraits of breast cancer. Molecular Oncology. 2011;5(1):5–23. doi:10.1016/j.molonc.2010.11.00321147047
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): breast Cancer. Version 2.2017. Available athttps://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 827, 2018.
   Google Scholar
• LobbezooDJA, Van KampenRJW, VoogdAC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Research and Treatment. 2013;141(3):507–514. doi:10.1007/s10549-013-2711-y24104881
   PubMed Web of Science ®Google Scholar
• ChangE, MougalianSS, AdelsonKB, YoungMR, YuJB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research and Treatment. 2019;173(1):209–216. doi:10.1007/s10549-018-4968-730242577
   PubMed Web of Science ®Google Scholar
• LargillierR, FerreroJM, DoyenJ, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19(12):2012–2019. doi:10.1093/annonc/mdn42418641006
   PubMed Web of Science ®Google Scholar
• WishartGC, BajdikCD, AzzatoEM, et al. A population-based validation of the prognostic model PREDICT for early breast cancer. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2011;37(5):411–417. doi:10.1016/j.ejso.2011.02.001
   PubMed Web of Science ®Google Scholar
• CoatesAS, WinerEP, GoldhirschA, et al. Tailoring therapies–improving the management of early breast cancer: st Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–1546. doi:10.1093/annonc/mdv22125939896
   PubMed Web of Science ®Google Scholar
• CianfroccaM, GoldsteinLJ. Prognostic and predictive factors in early-stage breast cancer. The Oncologist. 2004;9(6):606–616. doi:10.1634/theoncologist.9-6-60615561805
   PubMed Web of Science ®Google Scholar
• Systematic Reviews. Centre for Reviews and Dissemination. University of York; 2009. Available from:https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf. Accessed 8 2019.
   Google Scholar
• HuttonB, SalantiG, CaldwellDM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Int Med. 2015;162(11):777–784. doi:10.7326/M14-238526030634
   PubMed Web of Science ®Google Scholar
• HigginsJ, ThomasJ, ChandlerJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. 2019.
   Google Scholar
• BallmanKV. Biomarker: predictive or Prognostic?J Clin Oncol. 2015;33(33):3968–3971. doi:10.1200/JCO.2015.63.365126392104
   PubMed Web of Science ®Google Scholar
• DavisP, HaydenJ, SpringerJ, BaileyJ, MolinariM, JohnsonP. Prognostic factors for morbidity and mortality in elderly patients undergoing acute gastrointestinal surgery: a systematic review. Can J Surg. 2014;57(2):E44–E52.24666459
   PubMed Web of Science ®Google Scholar
• HaydenJA, van der WindtDA, CartwrightJL, CoteP, BombardierC. Assessing bias in studies of prognostic factors. Ann Internal Med. 2013;158(4):280–286. doi:10.7326/0003-4819-158-4-201302190-0000923420236
   PubMed Web of Science ®Google Scholar
• ArcieroCA, YangJ, PengL, et al. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treatment. 2017;166(3):743–755. doi:10.1007/s10549-017-4484-1
   PubMed Web of Science ®Google Scholar
• SchiavonG, HrebienS, Garcia-MurillasI, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):no pagination. doi:10.1126/scitranslmed.aac7551
   Web of Science ®Google Scholar
• GiordanoA, GiulianoM, De LaurentiisM, et al. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treatment. 2011;129(2):451–458. doi:10.1007/s10549-011-1645-5
   PubMed Web of Science ®Google Scholar
• UyeturkU, OksuzogluB, AkmanT, et al. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology. Med Oncol. 2014;31(4):929. doi:10.1007/s12032-014-0929-024659267
   PubMed Web of Science ®Google Scholar
• GoetzMP, O’ShaughnessyJ, SledgeGW, et al. The benefit of abemaciclib in prognostic subgroups: an exploratory analysis of combined data from the MONARCH 2 and 3 studies. Cancer Res Conf. 2017;78(4 Supplement):1.
   Web of Science ®Google Scholar
• SuhKJ, KimSH, LeeKH, et al. Bilateral Salpingo-oophorectomy compared to gonadotropin-releasing hormone agonists in premenopausal hormone receptor-positive metastatic breast cancer patients treated with aromatase inhibitors. Cancer Res Treatment. 2017;49(4):1153–1163. doi:10.4143/crt.2016.463
   Google Scholar
• XiongZ, DengG, HuangX, et al. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manage Res. 2018;10:287–295. doi:10.2147/CMAR.S155524
   PubMed Web of Science ®Google Scholar
• GilabertM, BertucciF, EsterniB, et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res. 2011;31(3):1079–1086.21498742
   PubMed Web of Science ®Google Scholar
• BonottoM, GerratanaL, Di MaioM, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast. 2017;31:114–120. doi:10.1016/j.breast.2016.10.02127837704
   PubMed Web of Science ®Google Scholar
• PaolettiC, ReganMM, LiuMC, et al. Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: results of the COMETI Phase 2 trial. Cancer Res Conf. 2017;77(4Supplement 1).
   Google Scholar
• PapadakiMA, StoupisG, TheodoropoulosPA, MavroudisD, GeorgouliasV, AgelakiS. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2018;06:06.
   Google Scholar
• XieJ, HaoY, LiN, et al. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol. 2015;4(1):31. doi:10.1186/s40164-015-0023-026693096
   PubMedGoogle Scholar
• GriguoloG, PouderouxS, DieciMV, et al. Clinical presentation and outcome of leptomeningeal metastasis in patients with breast cancer in relation to histology and tumor subtypes. Cancer Res Conf. 2017;78(4 Supplement):1.
   Google Scholar
• GuoX, XuJ, YingE, YuZ, SunT. Correlation between hormone receptor status and depressive symptoms in patients with metastatic breast cancer. Oncotarget. 2017;8(31):50774–50781. doi:10.18632/oncotarget.1503728881602
   PubMedGoogle Scholar
• PeetersDJE, Van DamPJ, Van Den EyndenGGM, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer. 2014;110(2):375–383. doi:10.1038/bjc.2013.74324366294
   PubMed Web of Science ®Google Scholar
• CinauseroM, GerratanaL, De CarloE, et al. Determinants of last-line treatment in metastatic breast cancer. Clinical Breast Cancer. 2018;18(3):205–213. doi:10.1016/j.clbc.2017.07.00828781022
   PubMed Web of Science ®Google Scholar
• GamucciT, MentucciaL, NatoliC, et al. A real-world multicentre retrospective study of paclitaxel-bevacizumab and maintenance therapy as first-line for HER2-negative metastatic breast cancer. J Cell Physiol. 2017;232(6):1571–1578. doi:10.1002/jcp.2568527861874
   PubMed Web of Science ®Google Scholar
• YamamuraJ, KamigakiS, FujitaJ, OsatoH, KomoikeY. The difference in prognostic outcomes between de novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2-negative Breast Cancer. Vivo (Athens, Greece). 2018;32(2):353–358.
   PubMed Web of Science ®Google Scholar
• MiyoshiY, ShienT, OgiyaA, et al. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. Breast Cancer Research. 2016;18(1):73. doi:10.1186/s13058-016-0731-327368476
   PubMed Web of Science ®Google Scholar
• ChenX, FanY, XuB. Distinct characteristics and metastatic behaviors of late recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a single institute experience of more than 10 years. Clinical Breast Cancer. 2018.
   Web of Science ®Google Scholar
• GampenriederSP, RinnerthalerG, HacklH, et al. DNA methylation signatures predicting bevacizumab efficacy in metastatic breast cancer. Theranostics. 2018;8(8):2278–2288. doi:10.7150/thno.2354429721079
   PubMed Web of Science ®Google Scholar
• JungSY, SereikaSM, LinkovF, BrufskyA, WeissfeldJL, RosenzweigM. The effect of delays in treatment for breast cancer metastasis on survival. Breast Cancer Res Treatment. 2011;130(3):953–964. doi:10.1007/s10549-011-1662-4
   PubMed Web of Science ®Google Scholar
• KorantzisI, KalogerasKT, PapaxoinisG, et al. Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel. Anticancer Res. 2012;32(10):4569–4580.23060588
   PubMed Web of Science ®Google Scholar
• InariH, SuganumaN, KawachiK, et al. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. BMC Cancer. 2017;17(1):160. doi:10.1186/s12885-017-3154-328241804
   PubMed Web of Science ®Google Scholar
• MotomuraK, IshitobiM, KomoikeY, et al. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology. 2010;79(1–2):55–61. doi:10.1159/00031954021071990
   PubMed Web of Science ®Google Scholar
• JacotW, MazelM, MolleviC, et al. Expression of PD-L1 on circulating breast cancer cells: correlation with clinicopathologic data and impact on prognosis. Cancer Res Conf. 2018;78(13 Supplement):1.
   Web of Science ®Google Scholar
• JungSY, RosenzweigM, SereikaSM, LinkovF, BrufskyA, WeissfeldJL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23(1):103–112. doi:10.1007/s10552-011-9859-822037907
   PubMed Web of Science ®Google Scholar
• KontaniK, HashimotoSI, MurazawaC, et al. Factors responsible for long-term survival in metastatic breast cancer. World J Surg oncol. 2014;12(1):344. doi:10.1186/1477-7819-12-34425395387
   PubMed Web of Science ®Google Scholar
• PistilliB, Lardy-CleaudA, JacquetE, et al. FICHE-YOUNG: fIrst-line treatment CHoicE in hormone receptor positive (HR1)/HER2-negative metastatic breast cancer patients (MBC) 45 years old. A large observational multicenter cohort survival analysis. Ann Oncol. 2017;28(Supplement 5):v92–v93. doi:10.1093/annonc/mdx365.043
   Google Scholar
• PiergaJY, HajageD, BachelotT, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23(3):618–624. doi:10.1093/annonc/mdr26321642515
   PubMed Web of Science ®Google Scholar
• BoudinL, ChabannonC, SfumatoP, et al. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. Eur J Cancer. 2016;57:118–126. doi:10.1016/j.ejca.2016.01.00526918737
   PubMed Web of Science ®Google Scholar
• KobayashiK, ItoY, MatsuuraM, et al. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today. 2016;46(7):821–826. doi:10.1007/s00595-015-1252-x26467559
   PubMed Web of Science ®Google Scholar
• LobbezooDJA, Van KampenRJW, VoogdAC, et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands breast cancer consortium. Ann Oncol. 2016;27(2):256–262. doi:10.1093/annonc/mdv54426578730
   PubMed Web of Science ®Google Scholar
• GongY, ZhangJ, JiP, LingH, HuX, ShaoZ-M. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Med . 2018;7(8):4156–4169. doi:10.1002/cam4.166829984914
   PubMed Web of Science ®Google Scholar
• FountzilasG, KotoulaV, PectasidesD, et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative Phase II trial. PLoS One. 2013;8(7):e69256. doi:10.1371/journal.pone.006925623935969
   PubMed Web of Science ®Google Scholar
• DelpechY, WuY, HessKR, et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treatment. 2012;135(2):619–627. doi:10.1007/s10549-012-2194-2
   PubMed Web of Science ®Google Scholar
• RedondoA, Ramos VazquezM, MansoL, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. OncoTargets Ther. 2018;11:5845–5852. doi:10.2147/OTT.S170303
   PubMed Web of Science ®Google Scholar
• ManuelM, TredanO, BachelotT, et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. OncoImmunology. 2012;1(4):432–440. doi:10.4161/onci.1954522754761
   PubMed Web of Science ®Google Scholar
• ZhangJ, JiaZ, RagazJ, et al. The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. BMC Cancer. 2013;13:42. doi:10.1186/1471-2407-13-4223368410
   PubMed Web of Science ®Google Scholar
• AversaC, RossiV, GeunaE, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast. 2014;23(5):623–628. doi:10.1016/j.breast.2014.06.00924993072
   PubMed Web of Science ®Google Scholar
• Ayala de la PeñaF, Yufera SolerJC, IvarsMA, et al. Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer. Ann Oncol. 2017;28(Supplement 5):v94. doi:10.1093/annonc/mdx365.046
   Google Scholar
• GerratanaL, FanottoV, BonottoM, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32(2):125–133. doi:10.1007/s10585-015-9697-225630269
   PubMed Web of Science ®Google Scholar
• BonechiM, GalardiF, BiagioniC, et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018;9(23):16389–16399. doi:10.18632/oncotarget.2470029662653
   PubMedGoogle Scholar
• PascualT, Apellaniz-RuizM, PernautC, et al. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS One. 2017;12(7):e0180192. doi:10.1371/journal.pone.018019228727815
   PubMed Web of Science ®Google Scholar
• OgiyaA, YamazakiK, HoriiR, et al. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 2017;24(3):473–482. doi:10.1007/s12282-016-0730-327628678
   PubMed Web of Science ®Google Scholar
• OkazakiM, HorimotoY, TanabeM, et al. Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. Med Oncol. 2018;35(4):48. doi:10.1007/s12032-018-1112-929520681
   PubMed Web of Science ®Google Scholar
• ChandarlapatyS, ChenD, HeW, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the bolero-2 Clinical Trial. JAMA Oncol. 2016;2(10):1310–1315. doi:10.1001/jamaoncol.2016.127927532364
   PubMed Web of Science ®Google Scholar
• LobbezooDJA, Van KampenRJW, VoogdAC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?British Journal of Cancer. 2015;112(9):1445–1451. doi:10.1038/bjc.2015.12725880008
   PubMed Web of Science ®Google Scholar
• ZhaoX, XuX, ZhangQ, et al. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving “metronomic” zoledronic acid. BMC Cancer. 2011;11:403. doi:10.1186/1471-2407-11-40321936956
   PubMed Web of Science ®Google Scholar
• Llombart-CussacA, PivotX, BiganzoliL, et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast. 2014;23(5):656–662. doi:10.1016/j.breast.2014.06.01725047747
   PubMed Web of Science ®Google Scholar
• KawanoA, ShimizuC, HashimotoK, et al. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. Breast Cancer. 2013;20(2):145–151. doi:10.1007/s12282-011-0320-322139727
   PubMed Web of Science ®Google Scholar
• RenZ, LiY, ShenT, HameedO, SiegalGP, WeiS. Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis. Pathology Research and Practice. 2016;212(1):24–30. doi:10.1016/j.prp.2015.11.003
   PubMed Web of Science ®Google Scholar
• JanssonS, BendahlPO, LarssonAM, AaltonenKE, RydenL. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16(1):433. doi:10.1186/s12885-016-2406-y27390845
   PubMed Web of Science ®Google Scholar
• MullerV, RiethdorfS, RackB, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch SystemTM and AdnaTest BreastTM in metastatic breast cancer patients: the DETECT study. Breast Cancer Research. 2012;14(4):R118. doi:10.1186/bcr324322894854
   PubMed Web of Science ®Google Scholar
• WallwienerM, HartkopfAD, BaccelliI, et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treatment. 2013;137(2):503–510. doi:10.1007/s10549-012-2382-0
   PubMed Web of Science ®Google Scholar
• BeijeN, OnstenkW, KraanJ, et al. Prognostic Impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor. Neoplasia (United States). 2016;18(11):647–653. doi:10.1016/j.neo.2016.08.007
   PubMed Web of Science ®Google Scholar
• LeoneBA, VallejoCT, RomeroAO, et al. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treatment. 2017;161(3):537–548. doi:10.1007/s10549-016-4066-7
   PubMed Web of Science ®Google Scholar
• NiederC, DalhaugA, HauklandE, MannsakerB, PawinskiA. Prognostic Impact of the Tumor Marker CA 15-3 in##. J Clin Med Res. 2017;9(3):183–187. doi:10.14740/jocmr2653w28179964
   PubMedGoogle Scholar
• CarbogninL, SperdutiI, CiccareseM, et al. Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: implications for post-progression and conditional survival. Breast. 2016;29:24–30. doi:10.1016/j.breast.2016.06.02127394675
   PubMed Web of Science ®Google Scholar
• StaudiglC, ConcinN, GrimmC, et al. Prognostic relevance of pretherapeutic gamma-glutamyltransferase in patients with primary metastatic breast cancer. PLoS One. 2015;10(4):e0125317. doi:10.1371/journal.pone.012531725915044
   PubMed Web of Science ®Google Scholar
• ParkS, YoonJK, Jin LeeS, KangSY, YimH, AnYS. Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis. Medicine (United States). 2017;96(50):e8985.
   Google Scholar
• MunzoneE, BotteriE, SandriMT, et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clinical Breast Cancer. 2012;12(5):340–346. doi:10.1016/j.clbc.2012.07.00123040002
   PubMed Web of Science ®Google Scholar
• ElsamanyS, AlzahraniA, ElkhalikSA, et al. Prognostic value of mammographic breast density in patients with metastatic breast cancer. Medical Oncol. 2014;31(8):96. doi:10.1007/s12032-014-0096-3
   PubMed Web of Science ®Google Scholar
• Vaz-LuisI, LinNU, KeatingNL, et al. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treatment. 2015;151(3):697–707. doi:10.1007/s10549-015-3432-1
   PubMed Web of Science ®Google Scholar
• DemianSR, HamdyM, AliIM. The regulatory effects of interleukin-12 on interleukin-18 and interferon-gamma production in Egyptian breast cancer patients. Alexandria J Med. 2011;47(4):283–290. doi:10.1016/j.ajme.2011.07.016
   Google Scholar
• KonoM, FujiiT, MatsudaN, et al. Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Journal of Cancer. 2018;9(19):3640–3646. doi:10.7150/jca.2682530310523
   PubMed Web of Science ®Google Scholar
• BertautA, MounierM, DesmoulinsI, et al. Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status. European Journal of Cancer Care. 2015;24(6):920–928. doi:10.1111/ecc.1230625757548
   PubMed Web of Science ®Google Scholar
• DominiciL, NajitaJ, HughesM, et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Research & Treatment. 2011;129(2):459–465. doi:10.1007/s10549-011-1648-221713372
   PubMed Web of Science ®Google Scholar
• WuSG, ZhangWW, SunJY, et al. The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis. Oncotarget. 2017;8(40):67851–67860. doi:10.18632/oncotarget.1888928978078
   PubMedGoogle Scholar
• den BrokWD, SpeersCH, GondaraL, BaxterE, TyldesleySK, LohrischCA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Research and Treatment. 2017;161(3):549–556. doi:10.1007/s10549-016-4080-928000014
   PubMed Web of Science ®Google Scholar
• ErcolaniG, ZanelloM, SerenariM, et al. Ten-year survival after liver resection for breast metastases: a single-center experience. Digestive Surgery. 2018;35(4):372–380. doi:10.1159/00048652329393171
   PubMed Web of Science ®Google Scholar
• YerushalmiR, TyldesleyS, KenneckeH, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Annals of Oncology. 2012;23(2):338–345. doi:10.1093/annonc/mdr15421543625
   PubMed Web of Science ®Google Scholar
• Desille-GbaguidiH, AvigdorS, BodyG, OuldamerL. Survival impact of primary site surgery on metastatic breast cancer patients at diagnosis. Journal of Gynecology Obstetrics and Human Reproduction. 2018;21:21.
   Google Scholar
• KingTA, LymanJP, GonenM, et al. Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. Journal of Clinical Oncology. 2016;34(20):2359–2365. doi:10.1200/JCO.2015.63.196027001590
   PubMed Web of Science ®Google Scholar
• LawrieCH, GoicoecheaI, RezolaR, et al. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases. F1000Research. 2018;6:1606. doi:10.12688/f1000research.12393.2
   Google Scholar
• LauR, FuL, SamuelsM, et al. A targeted RNA-seq assay to measure activating ER mutations and ER/PR-associated gene expression predicts sensitivity to endocrine therapy for metastatic breast cancer. Cancer Res Conf. 2017;77(13 Supplement):1.
   Google Scholar
• TurkerI, ArslanUY, YaziciO, et al. Prognostic factors in operated stage IIIC, pathological N3a breast cancer patients. Breast Care. 2014;9(6):421–427. doi:10.1159/00036643825759625
   PubMed Web of Science ®Google Scholar
• PRISMA: transparent Reporting of Systematic Reviews and Meta-analyses. Available from::http://prisma-statement.org/Last. Accessed612, 2018.
   Google Scholar
• MarshallEM, BertautA, DesmoulinsI, et al. Prognostic factors of survival among women with metastatic breast cancer and impact of primary or secondary nature of disease on survival: a french population-based study. The Breast Journal. 2017;23(2):138–145. doi:10.1111/tbj.1271727935232
   PubMed Web of Science ®Google Scholar
• GeigerS, CnossenJA, HorsterS, DiGioiaD, HeinemannV, StemmlerHJ. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005. Anti-Cancer Drugs. 2011;22(9):933–939. doi:10.1097/CAD.0b013e32834860af21666437
   PubMed Web of Science ®Google Scholar
• KhanfirA, LahianiF, BouzguendaR, AyediI, DaoudJ, FrikhaM. Prognostic factors and survival in metastatic breast cancer: a single institution experience. Rep Pract Oncol Radiother. 2013;18(3):127–132. doi:10.1016/j.rpor.2013.01.00124416543
   PubMedGoogle Scholar
• JangRW, CaraiscosVB, SwamiN, et al. Simple prognostic model for patients with advanced cancer based on performance status. Journal of Oncology Practice. 2014;10(5):e335–e341. doi:10.1200/JOP.2014.00145725118208
   PubMedGoogle Scholar
• Di LeoA, O’ShaughnessyJ, SledgeGWJr, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ Breast Cancer. 2018;4:41. doi:10.1038/s41523-018-0094-230588487
   PubMed Web of Science ®Google Scholar
• GuptaV, HaqueI, ChakrabortyJ, GraffS, BanerjeeS, BanerjeeSK. Racial disparity in breast cancer: can it be mattered for prognosis and therapy. J Cell Commun Signal. 2018;12(1):119–132. doi:10.1007/s12079-017-0416-429188479
   PubMed Web of Science ®Google Scholar
• GanggayahMD, TaibNA, HarYC, LioP, DhillonSK. Predicting factors for survival of breast cancer patients using machine learning techniques. BMC Med Inform Decis Mak. 2019;19(1):48. doi:10.1186/s12911-019-0801-430902088
   PubMed Web of Science ®Google Scholar
• MartínezME, UnkartJT, TaoL, et al. Prognostic significance of marital status in breast cancer survival: a population-based study. PLoS One. 2017;12(5):e0175515. doi:10.1371/journal.pone.017551528475579
   PubMed Web of Science ®Google Scholar
• CardosoF, SenkusE, CostaA, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger. Ann Oncol. 2018;29(8):1634–1657. doi:10.1093/annonc/mdy19230032243
   PubMed Web of Science ®Google Scholar
• TangC, WangP, LiX, et al. Lymph node status have a prognostic impact in breast cancer patients with distant metastasis. PLoS One. 2017;12(8):e0182953. doi:10.1371/journal.pone.018295328806399
   PubMed Web of Science ®Google Scholar
• da CunhaA, Antoniazi MichelinM, Cândido MurtaEF. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. Immunology Letters. 2016;177:25–37. doi:10.1016/j.imlet.2016.07.00927423825
   PubMed Web of Science ®Google Scholar
• KarihtalaP, JääskeläinenA, RoininenN, JukkolaA. Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital. BMJ Open. 2020;10(10):e038798. doi:10.1136/bmjopen-2020-038798
   PubMed Web of Science ®Google Scholar
• GiordanoSH. Update on locally advanced breast cancer. The Oncologist. 2003;8(6):521–530. doi:10.1634/theoncologist.8-6-52114657530
   PubMed Web of Science ®Google Scholar
• YardleyDA, KaufmanPA, BrufskyA, et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 2014;145(3):725–734. doi:10.1007/s10549-014-2916-824706168
   PubMed Web of Science ®Google Scholar
• LambertiniM, FerreiraAR, Di MeglioA, et al. Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multicenter retrospective cohort study. Clinical Breast Cancer. 2017;17(8):601–610.e602. doi:10.1016/j.clbc.2017.04.00228479052
   PubMed Web of Science ®Google Scholar
• den BakkerCM, AnemaJR, ZamanA, et al. Prognostic factors for return to work and work disability among colorectal cancer survivors; a systematic review. PLoS One. 2018;13(8):e0200720. doi:10.1371/journal.pone.020072030110333
   PubMed Web of Science ®Google Scholar
• ThompsonJY, ByrneC, WilliamsMA, KeeneDJ, SchlusselMM, LambSE. Prognostic factors for recovery following acute lateral ankle ligament sprain: a systematic review. BMC Musculoskeletal Disorders. 2017;18(1):421. doi:10.1186/s12891-017-1777-929061135
   PubMed Web of Science ®Google Scholar
• RushtonA, ZoulasK, PowellA, StaalJB. Physical prognostic factors predicting outcome following lumbar discectomy surgery: systematic review and narrative synthesis. BMC Musculoskeletal Disorders. 2018;19(1):326. doi:10.1186/s12891-018-2240-230205812
   PubMed Web of Science ®Google Scholar